Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD

In this multicenter phase II study, we evaluated the safety and efficacy of imatinib in patients with steroid-resistant chronic graft-versus-host disease (cGVHD) and evaluated the quality of life (QOL) of the enrolled patients using the Short Form 36 (SF-36) health survey questionnaire. Thirty-six p...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Dong Won, Cho, Hee Jeong, Kim, Ju-Hyung, Ahn, Jae Sook, Kim, Hyeoung-Joon, Lim, Sung Nam, Cheong, Jun Won, Kim, Sung-Yong, Lee, Ho Sup, Won, Jong Ho, Yhim, Ho-Young, Sohn, Sang Kyun, Moon, Joon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310209/
https://www.ncbi.nlm.nih.gov/pubmed/35861214
http://dx.doi.org/10.1177/09636897221113789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310209/
https://www.ncbi.nlm.nih.gov/pubmed/35861214
http://dx.doi.org/10.1177/09636897221113789

Ejemplares similares